Market Place
Sourcing Support
CND Life Sciences Uses Syn-One In Ph2 Trial Parkinson’s Endpoint
11 Nov 2025 //
PR NEWSWIRE
Ablin Therapeutics Releases Phase 2 Trial Results
09 Oct 2025 //
GLOBENEWSWIRE
ABLi Therapeutics to Speak at 2025 Parkinson’s Disease Congress
15 Sep 2025 //
GLOBENEWSWIRE
Inhibikase Therapeutics Reports Q2 Financial Results And Recent Activity
14 Aug 2024 //
GLOBENEWSWIRE
Inhibikase Completes Enrollment Of Phase 2 Trial For Risvodetinib In Parkinson’s
17 Jun 2024 //
GLOBENEWSWIRE
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib
07 Mar 2024 //
GLOBENEWSWIRE
Inhibikase Announces Publication Highlighting Results from Ph 1 with Risvodetinib
29 Jan 2024 //
GLOBENEWSWIRE
Inhibikase Highlights Functional Analysis from the 201 Trial of Risvodetinib
16 Oct 2023 //
GLOBENEWSWIRE
Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib
04 Oct 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.